VIA
INFI

Vident Investment Advisory’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Vident Investment Advisory’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-26,964
Closed -$295K – 1171
2015
Q2 		$295K Buy
26,964
+1,002
+4% +$12.9K 0.04% 687
2015
Q1 		$363K Buy
+25,962
New +$397K 0.07% 581

Other funds holding INFI

ACM
Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vident Investment Advisory's INFI Position: Q3 2015 in Review

Vident Investment Advisory sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2015, closing a stake of 26,964 shares — an estimated $295K sold.

Vident Investment Advisory first reported a position in INFI in Q1 2015 and held it in 2 quarters. The position peaked at $363K in Q1 2015. 129 funds tracked by Wall St. Rank hold INFI as of Q3 2015.

  • Vident Investment Advisory reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 26,964 Infinity Pharmaceuticals, Inc. shares in Q3 2015, an estimated $295K.
  • Vident Investment Advisory first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • Vident Investment Advisory's Infinity Pharmaceuticals, Inc. position peaked at $363K in Q1 2015.
  • 129 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2015.

Based on Vident Investment Advisory's 13F filing for Q3 2015, filed 26 Oct 2015.